# GPT-6 Astra / inf-k01

Original final answer, shared by both scoring rounds.

## Bottom line

**E1 identifies a trait-associated locus, not a causal SNP or an effector gene.** The lead noncoding SNP is a candidate causal variant, but it may simply tag another variant through linkage disequilibrium (LD). Its proximity to **G** does not establish that G mediates the association. **H, another gene, multiple genes, or a mechanism not involving altered gene expression remain possible.**

The recommended next step is **statistical fine mapping using appropriate LD information**, followed by integration with relevant molecular-QTL data where available. Functional experiments should test the resulting hypotheses—not begin by assuming that the lead SNP acts through G.

All locus-specific evidence below comes from **E1**. No fine-mapping, colocalization, or perturbation results are supplied.

## 1. Explicit evidence-to-inference-to-conclusion chain

| Evidence supplied in E1 | Permitted inference | Conclusion and limit |
|---|---|---|
| A well-controlled GWAS identifies a lead SNP. | Genotype at that SNP is statistically associated with the studied trait. | There is evidence for a trait-associated locus. Association alone does not identify the causal variant or mechanism. |
| The lead SNP is noncoding and near G. | A regulatory mechanism involving G is a hypothesis worth testing. | Neither regulatory function nor G as the effector gene is established. Noncoding location does not itself demonstrate function. |
| Several linked variants span G and H. | Correlated inheritance could make several variants associate with the trait even if only one is causal. Multiple causal variants are also possible. | The lead SNP’s statistical prominence does not uniquely implicate it. The interval does not uniquely implicate G or H. |
| No functional or colocalization data are supplied. | There is no supplied evidence connecting a particular allele to a molecular change or target gene. | A specific chain such as “lead SNP → altered G expression → trait” remains untested. |

The conceptual causal chain to investigate is:

**Causal allele → molecular consequence in an appropriate biological context → effector-gene activity → phenotype contributing to the GWAS trait.**

The observed GWAS result is not that chain. It is an association that can arise because the measured lead SNP is correlated with the causal allele.

## 2. What the four steps mean—and do not mean

### A. Linkage disequilibrium: why association implicates a region

Here, “linked variants” is interpreted as variants correlated through **LD**: particular alleles are inherited together more often than expected by chance. This is not evidence that their nearby genes interact biologically.

If a causal variant influences the trait, nearby correlated variants can also show association. The lead SNP is the strongest statistical marker in the reported analysis; it is not necessarily the causal allele.

**What LD can establish:** the correlation structure relevant to interpreting and localizing the association.

**What it cannot establish:** which variant changes biology, which gene is affected, or whether the region contains one versus several causal signals.

**For E1:** the variants spanning G and H define ambiguity, not a demonstrated mechanism involving both genes.

### B. Fine mapping: which variants best explain the association?

Statistical fine mapping combines association evidence with LD information to compare candidate causal configurations. Depending on the method, it produces variant-level posterior inclusion probabilities and one or more **credible sets**.

**Proposed analysis:** obtain sufficiently complete locus-level association data and LD representative of the GWAS population. Assess whether there are multiple signals using an appropriate conditional or joint model, rather than forcing a single-causal-variant explanation.

**What fine mapping can establish:** under its assumptions, some variants are more statistically compatible with causing the association than others. A small credible set can substantially narrow experimental targets.

**What it cannot establish:**

- Biological causality simply because a variant receives a high posterior probability.
- A unique variant when candidates are too strongly correlated to distinguish.
- An effector gene merely because a prioritized variant lies near or within it.

Credible-set coverage depends on the statistical model, LD accuracy, variant coverage, priors, and causal-signal assumptions. Functional annotations can inform prioritization, but annotation-weighted support is not independent experimental validation.

**For E1:** no fine-mapping results are given. We cannot report credible-set membership, posterior probabilities, or a uniquely resolved variant.

### C. Colocalization: does the trait share a causal signal with a molecular phenotype?

Colocalization compares association patterns for two phenotypes—for example, the GWAS trait and expression or splicing of G or H.

The critical distinction is between:

- **A shared causal variant** affecting both phenotypes; and
- **Different causal variants in LD**, producing overlapping-looking association peaks.

An overlapping eQTL or the same apparent lead SNP is not, by itself, sufficient evidence of colocalization.

**Proposed analysis:** use relevant tissue- or cell-state-specific molecular-QTL data for G, H, and other plausible targets. Account for multiple signals and compatible variant coverage; assess sensitivity to model assumptions and priors.

**What colocalization can establish:** statistical support for a shared causal basis of the two association signals. For example, a shared GWAS–G-expression signal would strengthen G as a candidate effector gene.

**What it cannot establish:** that altered G expression mediates the trait association. A shared variant could affect G expression and the trait through separate pathways, or affect several genes. The direction and relevant context of the causal mechanism also require evidence.

Absence of colocalization is not always exclusion: molecular-QTL studies may lack power or sample the wrong context. In E1, however, there is **no colocalization result at all**, not a negative result.

Fine mapping and colocalization are complementary and can be integrated; they are not necessarily a rigid sequence.

### D. Functional perturbation: does changing the candidate cause the predicted effects?

Experiments intervene on a variant, regulatory element, or gene. These interventions answer different questions.

| Proposed intervention | What a positive result supports | Important limit |
|---|---|---|
| Precise endogenous editing of a candidate allele | That allele changes measured molecular or cellular phenotypes in the tested system. | Does not alone show that those effects explain the human GWAS association. |
| Deletion or CRISPR interference of a candidate regulatory region | The region regulates a measured target or phenotype. | Does not identify the causal nucleotide; a large perturbation may differ from the natural allele’s effect. |
| Reporter assay | Sequence-dependent regulatory activity in the assay. | May not reproduce endogenous chromatin, target-gene choice, or physiological context. |
| Perturbation of G or H | The gene can influence the measured phenotype. | Does not link the GWAS variant to that gene. |

**Proposed stronger test:** edit prioritized alleles in a justified biological system, measure effects on G, H, and other plausible targets, and assess a trait-relevant phenotype. Then test whether a directionally appropriate gene perturbation reproduces the allele effect and whether restoring the implicated gene activity rescues it. Include appropriate editing controls and independent replication.

Concordant results would support the mechanistic chain more strongly than any single assay. They would still be bounded by model relevance, perturbation magnitude, specificity, and how closely the experimental phenotype represents the GWAS trait.

## 3. Alternatives and what would change the conclusion

Currently compatible explanations include:

1. The lead SNP acts through G.
2. A linked variant acts through G.
3. The lead SNP or another variant acts through H or a more distant gene.
4. Multiple variants or genes contribute.
5. A mechanism other than altered steady-state expression explains the association.

**Unreported parameters:** trait identity, ancestry, sample size, effect sizes, LD strength, variant coverage, relevant biological context, and molecular-QTL availability. These prevent locus-specific ranking and experimental design.

A robustly resolved fine-mapped variant would narrow the **variant** hypothesis. Relevant colocalization would strengthen a **gene or molecular-process** hypothesis. Concordant endogenous allele editing, target-gene effects, and gene-level rescue would strengthen **mechanistic causality**.

**Current defensible conclusion:** E1 supports a GWAS-associated locus near G with unresolved causal variant(s) and effector gene(s). Calling either the lead SNP causal or G the effector would exceed the supplied evidence.
